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A B S T R A C T
Purpose: The study was conducted to assess the long-term outcome of antiepileptic drug (AED) treatment
in drug-naïve patients with cavernous malformation (CM) related epilepsy (CRE).
Method: This is a retrospective, single-center, long-term observational study of 34 patients with
previously untreated seizures related to CM. All patients were followed-up for at least two years. Drug
resistant epilepsy (DRE) was deﬁned as two or more seizures per year after trial of two appropriate AEDs.
Patients who had only one seizure during the previous one year were assigned as “epilepsy with rare
seizures (ERSs)”.
Results: Terminal 1-year seizure remission (1-YTR) was achieved in 22 (64.7%) patients, nine (26.5%)
patients were diagnosed as DRE, and three (8.8%) patients were as ERSs. 1-YTR was achieved in 18 (52.9%)
patients by the ﬁrst drug regimen and in additional four (11.8%) patients by the second drug regimen.
None of nine patients who failed to ﬁrst two drug regimens did achieve 1-YTR. The location of CM in the
temporal lobe was the only prognostic factor predicting a poor seizure outcome (p = 0.012).
Conclusion: The outcome of AEDs therapy in patients who were presented with new onset of CRE was
quite comparable with that of patients with newly diagnosed epilepsy. Failure to achieve seizure-free
after adequate trials of two AEDs seems appropriate as the criteria for their referral to surgical treatment.
For patients with temporal lobe CRE, earlier presurgical evaluation may be considered justiﬁable once
they failed to an adequate trial of the ﬁrst drug.
© 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Cavernous malformation (CM) is the second most common
type of vascular malformation. An epileptic seizure is the most
common presenting symptom of CM, which is followed by focal
neurological deﬁcits, acute hemorrhage, and headache [1].Abbreviations: CM, cavernous malformation; CRE, CM-related epilepsy; AED,
antiepileptic drug; 1-YTR, terminal 1 year remission; YR, year seizure remission;
SFR, seizure-free rate; MRI, magnetic resonance image; ILAE, International League
Against Epilepsy; DRE, drug resistant epilepsy; EEG, electroencephalography; ERSs,
epilepsy with rare seizures; GP, good prognosis; PP, poor prognosis; IED,
interictalepileptiform discharges; CBZ, carbamazepine; LTG, lamotrigine; VPA,
valproate; RCT, randomized controlled trial; TLE, temporal lobe epilepsy; MTLE,
mesial TLE; HS, hippocampal sclerosis.
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1059-1311/© 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights resSupratentorial location, cortical involvement and archicortical
and mesiotemporal location are established risk factors of CM-
related epilepsy (CRE) [2].
A prospective population-based registry reported that 5-year
risk of ﬁrst-ever seizure after the presentation of incidental CM
was 4%, while 5-year risk of epilepsy (or second seizure) after
ﬁrst-ever seizure in patients with CM was 94%, which has
provided a strong evidence for starting antiepileptic drug (AED)
therapy in patients with a single seizure related to CM [3]. In this
study, 2-year seizure remission (YR) rate by AED therapy at 5-year
follow-up period was 47%, which was lower than the 2-year
seizure remission rate (68%) in a community based study [4]. On
the other hand, a large outpatient clinic database found that the
seizure-free rate (SFR) in patients with vascular malformation
related epilepsy was 50%, which was better than that of patients
with normal magnetic resonance image (MRI) (42%), due to head
trauma (30%), cortical dysplasia (24%), and hippocampal sclerosis
(11%) [5]. However, long-term outcomes of AED therapy in a pureerved.
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evidence-based guidelines for the management of newly diag-
nosed patients with CRE are not available yet.
Recent International League Against Epilepsy (ILAE)-report
stated that it was not necessary to wait until the rigorous criteria of
drug resistant epilepsy (DRE) proposed by ILAE [6] being fulﬁlled
but the failure to an appropriately conducted ﬁrst drug trial should
be considered sufﬁcient to recommend a presurgical evaluation
[2]. This statement seems to reﬂect current expert’s opinions
rather than evidence-based practice guidelines [7]. Decision about
the optimal timing of patient’s referral to surgery needs to be
individualized and should be based on accurate risk-beneﬁt
assessment for surgery, which requires reliable longitudinal
outcome data of AEDs therapy in patients with newly diagnosed
CRE. The study was conducted to investigate the long-term
outcome of AEDs therapy and related prognostic factors in patients
with newly diagnosed CRE.
2. Methods
2.1. Patients and treatment
We conducted a retrospective analysis of Yonsei Epilepsy
Registry, a prospective patient registry, which was described in
detail in a previous study [8]. Among 73 patients who were
registered under the diagnosis of untreated CRE during the period
between 2000 and 2013, 34 patients satisﬁed the patient’s
inclusion criteria, which were: (1) well-established diagnosis of
partial epilepsies as deﬁned by the International Classiﬁcation of
Epilepsies and Epileptic Syndromes [9]; (2) presence of CM by
brain MRI; (3) performed electroencephalography (EEG)
evaluation; (4) history of two or more seizures in the past with
at least one episode of seizure during the previous year before
the commencement of AEDs therapy, (5) follow-up of at least two
years. Thirty-nine patients were excluded from the study due to
previous surgery for CM (n = 13), less than two-year follow-up
(n = 11), previous AED therapy before their referral (n = 10), epilepsy
not related to CM (coincidental MRI ﬁnding) because of seizure
semiology or focal epileptiform discharges or slowing on EEG
inconsistent with CM location (n = 2), no EEG evaluation (n = 2), and
no seizure event during the last one year before treatment (n = 1).
The age at seizure onset, gender, duration of illness, seizure
frequencies before and after treatment, EEG and brain MRI
ﬁndings, prescribed AEDs and surgical information were docu-
mented. Epilepsy syndrome and seizure classiﬁcation were based
on thorough clinical assessment [9], and careful clinical correla-
tions with EEG and brain MRI. Patients usually visited the clinic at
one to six month intervals and their seizure frequency was
assessed at every clinic visit. AEDs therapy consisted of initial
monotherapy of the ﬁrst-line drugs for partial-onset seizures. If
patients developed seizure recurrences during adequate trials of
the ﬁrst drug regimen, second drug was chosen and tried either in
substitution monotherapy or combination therapy. If the ﬁrst drug
was discontinued due to emergence of adverse effects at lower
doses than its usual target dose, the drug trial was not considered
adequate to be counted as the ﬁrst drug regimen. Caring
epileptologists were fully responsible for the drug regimens
during the follow-up period.
We received approval from the Yonsei University Severance
Hospital ethical standards committee on human experimentation
for experiments using human subjects.
2.2. Evaluations and assessments
EEG and brain MRI were acquired in all patients. Brain
MRI sequences included T2-weighted axial slices with a regularhigh-resolution MRI unit (22 patients with 1.5-T and 12 patients
with 3.0-T) [10]; range of in-plane resolution 0.449–0.898 mm;
slice thickness 1–5 mm; slice spacing 1–2 mm. A neuroradiologist
and a neurologist evaluated the MRI data for each patient
independently to assess the number, side, localization, and
maximal diameter of CM by using a predeﬁned form, which was
followed by a joint session for harmonizing the differences in
interpretation. The location of CM was classiﬁed as temporal,
frontal, parietal, occipital and infratentorial lesions. In patients
with multiple CMs, the localization of epileptogenic lesion was
determined to the lobe harboring the lesion correlating with the
patient’s seizure descriptions, EEG features, or the largest lesion if
their correlations were not clear. The maximal diameter of CM
without hemosiderin rim was measured and divided by different
cutoff values, which were 10 mm and 20 mm respectively. Baseline
seizure frequency was deﬁned as monthly seizure frequency by
counting seizure numbers during the last three months in patients
having monthly seizures or during the last 12 months in patients
with less frequent seizures before the commencement of AEDs
therapy. After AEDs therapy, seizure frequency was calculated at
each clinic visits and assessed annually as seizure-free or not
seizure-free until the last follow-up visit. 1-YR was deﬁned as
freedom from seizure for 12 months during each year of follow-up,
whereas 1-YTR indicated no seizure during the last one year of
follow-up. If there was only one seizure during the year, we
categorize them as epilepsy with rare seizures (ERSs). If there were
two or more seizure recurrences during one year after adequate
trial of second drug regimen, DRE was diagnosed. Patients were
divided into two groups according to the achievement of 1-YTR;
patients who have achieved 1-year TSR were assigned to good
prognosis (GP) group, whereas poor prognosis (PP) group included
patients who had seizure relapses during the last one year of follow
up (patients with DRE and ERSs).
2.3. Statistics
All data were expressed as mean  standard deviation, and
median values were calculated. For subgroup analysis, the Chi-
square test or Fisher’s exact test were used for categorical variances
and independent two-sample t-test was performed for continuous
variables. Statistical analyses were performed using commercially
available software (SPSS, Ver. 20.0), and a two-tailed P
value < 0.05 was considered signiﬁcant.
3. Results
3.1. Demography and clinical characteristics
Mean baseline seizure frequency was 4.9  12.6 episodes per
month and median seizure frequency was 0.9 (interquartile range,
1.9) episodes per month. Seizure frequency was less than one per
month in 18 (52.9%) patients, one or more seizures per month in 14
(41.2%) patients, and daily seizures in two (5.9%) patients. Mean
duration of follow up was 5.9  3.2 years (range 2–12). CMs
responsible for patient’s seizure were located in the frontal lobe in
17 (50.0%) patients, temporal lobe in 15 (44.1%), and parietal lobe in
two (5.9%) patients. Six patients (17.6%) showed multiple CMs in
MRI and one of them had a positive family history of CM. Among
those with multiple CMs, four patients were assigned to the frontal
lobe epilepsy and one patient each to the temporal lobe and the
parietal lobe epilepsy on the basis of clinical-EEG and MRI
correlations (n = 3) or location of the largest lesion (n = 3). Mean
size of CM was 12.1 6.3 mm (range 4.2–31.5 mm). Lamotrigine
was the most frequently (23.5%) used AED for monotherapy,
whereas various combinations of AEDs were used for duo- or triple
drug therapy.
Fig. 1. Flowchart of overall seizure outcome.
1-YTR, seizure-free during the last one year of follow-up; ERS, epilepsy with rare seizure (only one episode of seizure relapse during the previous one year of follow-up); DRE,
drug resistant epilepsy (two or more seizures during the previous one year of follow-up); *, the patients achieved 1-YTR by the ﬁrst drug regimen; **, the patients achieved 1-
YTR by the second drug regimen.
Table 1
Demographic and clinical characteristics of the participants.
Total GP (n = 22) PP (n = 12) p-value
Age (year-old) 35.2  17.1 38.3  17.5 29.5  11.6 0.144
Sex (M/F) 20/14 14/8 6/6 0.487
Seizure duration (year) 6.1  8.6 5.3  3.1 6.9  3.2 0.168
Seizure frequency (monthly) 4.9  12.6 4.3  9.9 6.0  17.0 0.753
EEG ﬁndings
Normal/abnormal 17/17 11/11 6/6 >0.999
IEDs (+)/() 14/20 9/13 5/7 >0.999
Single/multiple lesion 28/6 16/6 12/0 0.069
Size of lesion 10 mm 6 6 0.265
Size of lesion 20 mm 19 12 0.537
Temporal/extratemporal
location
15/19 6/16 9/3 0.012
Numerical values are presented as mean  standard deviation or number of cases.
GP, good prognosis group; PP, poor prognosis group; n, number; M, male; F, female;
EEG, electroencephalography; IED, interictalepileptiform discharges.
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Nineteen patients achieved 1-YR immediately after the ﬁrst
drug treatment but seizures relapsed in four of them. Among
those who did relapse, two patients were ERSs and were
followed-up with gradual dose-escalations of the ﬁrst drug,
whereas two other patients underwent trials of the second drug
regimen with achievement of 1-YTR in one and failure to achieve
seizure remission in the other. Among 15 patients who have failed
to achieve seizure remission during the ﬁrst year after the ﬁrst
drug, three patients achieved 1-YTRafter dose escalation of the
ﬁrst drug and another three patients by the trial of second drug
regimen. Therefore, 1-YTR was achieved in 64.7% (22/34) and
cumulative 1-YR was achieved in 73.5% (25/34) during the follow-
up, which was quite comparable to the outcome of hospital-based
cohort study of newly diagnosed epilepsy [11]. Nine patients
(26.5%) continued to have seizure recurrences despite of adequate
trials of ﬁrst two AEDs, thus satisﬁed the criteria of DRE. In
summary, the ﬁrst drug regimen successfully controlled seizures
in 18 patients (52.9%) and the second drug regimen was
successful in four of 13 (30.8%) patients who failed to the ﬁrst
drug. AEDs were withdrawn in two patients after prolonged
seizure remission by their strong desire to be free of AEDs, and
have been remaining seizure-free for three and ﬁve years each.
Among 12 (35.3%) patients who failed to the adequate trials of
second drug regimen, none achieved 1-YTR by further drug trials
(six under duotherapy, two under triple drug combination, and
one under ﬁve drug combination therapy), thus they were
assigned to PP group. Remaining three patients who had ERSs
during the ﬁrst drug trial were kept on the ﬁrst drug monotherapy
with progressive dose-escalations by the judgment of caring
physicians and assigned to PP group (Fig. 1).3.3. Clinical variables related with the outcome of AEDs therapy
Twenty two (64.7%) patients assigned to GP group and 12
(35.3%) were assigned into PP group. Multiple clinical variables
including age of seizure onset, seizure frequency before
treatment, duration of illness, numbersand size of CM, and EEG
features, were compared between GP and PP groups. None of
these variables were found signiﬁcantly different except the
location of CM, which was the only one prognostic factor
signiﬁcantly correlating with the outcome of AEDs therapy
(Table 1). Among 15 patients with temporal CRE, four (26.7%)
achieved 1-YTR by the ﬁrst drug treatment compared to 14 of 19
(73.7%) patients with extratemporal CRE (p = 0.006). Among
Table 2
Comparison between characteristics of the temporal located CM and extratemporal
located CM.
Temporal CM
(n = 15)
Extratemporal CM
(n = 19)
p-value
Age (year-old) 36.3  18.3 34.3  16.6 0.750
Seizure duration (year) 6.4  2.8 5.5  3.5 0.390
Seizure frequency (monthly) 9.0  18.1 1.7  3.6 0.143
Size of lesion (mm) 10.3  5.1 13.5  6.9 0.133
Outcomes Number Number
1-year TSR 6 16
By the ﬁrst drug 4 14 0.006
By the second drug 2 2 >0.999
DRE 6 3 0.010
ERSs 3 0
Numerical values are presented as mean  standard deviation or number of cases.
n, number; CM, cavernous malformation; TSR, terminal seizure remission; DRE,
drug resistant epilepsy; ERSs, epilepsy with rare seizures.
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drug regimen, 2 patients (25%) achieved 1-YTR, whereas 2 of 5
(40%) patients with extratemporal CRE did achieve 1-year TSR by
the second drug regimen (Table 2).
3.4. Postoperative seizure outcome
Among six patients with drug-resistant temporal, 5 patients
underwent epilepsy surgery. Two patients underwent extensive
lesionectomies consisting of resection of the lesion and the
surrounding epileptogenic cortex indicated by intraoperative
electrocorticography. In remaining three patients, resections of
the lesion and surrounding hemosiderin rim were performed
without intraoperative electrocorticography. All patients achieved
Engel Class-1 outcome and no permanent neurological deﬁcits
were encountered after surgery. AEDs were successfully discon-
tinued in two patients without any recurrences of seizure (Table 3).
Remaining one patient with temporal CRE, who did not undergo
surgery after failure of second drug regimen, continued having
seizures under combination therapy of four AEDs during the
follow-up of 7 years.Table 3
The patients who underwent surgical intervention for cavernous malformation.
Patient Sex/age Seizure frequencya Size of CM (m
1 F/30 0.7 11.00 
2 M/22 0.7 10.09 
3 M/21 2 17.00 
4 F/53 60 14.42 
5 M/23 1 4.19 
F, female; M, male; CM, cavernous malformation; AED, antiepileptic drugs; CBZ, carbam
a Seizure frequency per month during last 3 months before treatment.
Table 4
The patients whose lesion changed in repeated brain magnetic resonance image.
Patient Size of CM
(mm)a
Location of
CMa
Reason of repeated brain
MRI
Interval to the ﬁrst
brain MRI
1 9.47 Frontal Seizure relapse 7 years 
Seizure relapse and left
leg weakness
9 years 
2 12.90 Frontal Routine follow up 3 years 
CM, cavernous malformation; MRI, magnetic resonance image; AED, antiepileptic drug
a Cavernous malformations with multiple lesions were classiﬁed to the lobe harboring
their correlations were not clear.3.5. Follow-up brain MRI
Of 34 patients, 20 patients including four patients with multiple
CMs underwent follow-up brain MRI. MRI was repeated as a
routine follow-up procedure in 15 patients (9 patients were in
1-YTR at the time of follow-up MRI) and for evaluation of seizure
recurrence of seizures in ﬁve patients. Mean duration of follow-up
was 2.3 years (range 0.5–13.0). Brain MRI showed no signiﬁcant
interval changes in 18 patients (90.0%) including six patients with
DREs. Two patients with multiple CMs in initial MRI showed
enlargement of CMs in follow-up MRI (risk of 10.0% per person year
of exposure) (Table 4). One patient repeated brain MRI twice. The
ﬁrst follow-up MRI was repeated to evaluate the seizure relapse
and showed development of hemorrhage and enlargement of the
CM in the right frontal lobe. He became seizure-free after a dose
escalation of the second drug (valproate). After two years, MRI was
repeated again because of another seizure relapse and develop-
ment of mild weakness of the left leg. MRI demonstrated further
enlargement of the same lesion which had shown hemorrhage and
enlargement in previous MRI. He became seizure-free and his left
leg weakness was recovered after substitution monotherapy with
topiramate. Therefore, in our study, two of four patients with
multiple CMs showed dynamic changes of CMs in follow-up MRI
but none of 15 patients with a single CM.
4. Discussion
This is a retrospective hospital-based, observational study to
investigate the long-term outcome of AED therapy in patients with
newly diagnosed CRE. The major ﬁndings of the present study were
as follows: (1) successful seizure outcome was achieved in 18 of 34
(52.9%) patients by the ﬁrst drug monotherapy and in four of 13
(30.8%) patients who had tried second drug regimen. None of
patients who failed to the second drug regimen achieved 1-YTR by
further drug trials, (2) the location of CM was the only one
prognostic factor of AEDs therapy; temporal CRE was associated
with worse prognosis than extratemporal CRE, and (3) dynamic
changes of CM in patients with CRE werefrequent in patients with
multiple CMs but not in patients with single CM.m) Surgery modality Engle Current AED
Extensive lesionectomy 1A None
Lesionectomy 1D CBZ
Extensive lesionectomy 1A LTG
Lesionectomy 1A CBZ
VPA
Lesionectomy 1A None
azepine; LTG, lamotrigine; VPA, valproate.
MRI changes Management
Enlargement and hemorrhage of the lesion at the right
superior and mesial frontal lobe
Escalation of
the AED
Enlargement the same lesion to 18.20 mm Change of the
AED
Enlargement to 17.96 mm No change of
AED
s.
 the CM responsible for the patient’s seizure, EEG features, or to the largest lesion if
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therapy in patients with newly diagnosed epilepsy. If an adequate
trial of the ﬁrst drug fails to control seizures, trials of the second
drug regimen either in monotherapy or combination therapy is the
next step of treatment [12]. Failure of seizure control by adequate
trials of two AEDs deﬁnes the diagnosis of DRE [6], in which referral
of patients to tertiary epilepsy care centers are strongly
recommended for further diagnostic precision and appropriate
therapeutic trials including epilepsy surgery. The long-term
outcome of further drug trials in patients who fulﬁlled the ILAE-
criteria of DRE is still unclear due to their complex clinical courses
characterized by delayed remissions or alternating periods of
remission and relapse. Recently, Choi et al. reported that further
drug trials in patients who failed to ﬁrst two AEDs resulted in a
prolonged terminal remission in 31% of patients, which was
inﬂuenced by the type of epilepsy syndromes and duration of
follow-up [13].
A prospective study of a pediatric cohort found that 28 of 128
(22%) patients who failed to previous trials of two AEDs achieved
3-YTR at the end of follow-up for 10.1 years [14]. The probability of
achieving 3-YTR was strongly related to the etiology of epilepsy;
11% in symptomatic epilepsy and 33% in non-lesional epilepsy
(p = 0.003). Another long-term observational study in 79 patients
who failed to  two AEDs within two years after diagnosis of
epilepsy [15], has shown that 34 (45.3%) patients became seizure-
free at the follow-up of 11.7 years. In the study, the neuroimaging
features being a single predictive factor for the long-term
outcome; SFR was 60% in patients with normal MRI and 9% in
patients with abnormal MRI. Therefore, symptomatic etiology or
MRI-lesions in patients who failed to adequate trials of two AEDs
seems sufﬁcient for consideration of earlier epilepsy surgery if
their lesion is surgically accessible, while patients with unknown
etiology or normal MRI may be better off with further systematic
AEDs therapy for a higher chance of seizure remission as well as
less favorable surgical outcomes. The poor outcome of further drug
trials in our patients who failed to ﬁrst two AEDs is in good
agreement with these studies and we are in a favor of the
recommendation for earlier surgical evaluations in patients with
CRE who failed to the ﬁrst two drug regimens.
Prediction of long-term outcomes in patients who failed to the
ﬁrst AED is less clear. A previous study reported that 29 of 72 (42%)
patients who failed to the ﬁrst drug became seizure-free at
8 years of follow up [16]. A recent follow-up study of the SANAD
trial reported that 70% of patients who failed to the ﬁrst drug trial
achieved 1-YR at 5 years of follow up and concluded that the
predictive accuracy of long-term outcome models after ﬁrst drug
failure was relatively low [17]. On the other hand, failure to the ﬁrst
drug trial was a strong prognostic factor in patients with temporal
lobe epilepsy (TLE). Dlugos et al. reported that the failure of ﬁrst
AED trial accurately predicted refractory TLE at 2 years after onset
[18]. Spooner et al. followed 64 children with TLE for median
13.7 years and found that a long-term seizure-free outcome was
achieved in none of 28 children with MRI-lesions compared to 19 of
36 patients with normal MRI [19]. In addition, a recent study for
the long-term trajectory of patients with DRE has shown that the
outcome of TLE was poorer than that of other lobar epilepsies [13].
These studies suggest that the long-term outcome of AEDs therapy
in patients with TLE is different from that of other types of focal
epilepsies, thus the likelihood of persistent pharmacoresistance
after the ﬁrst drug failure may be higher in patients with TLE,
especially in cases with associated MRI-lesions. The assumption
seems in good agreement with the results of the present study,
which has shown signiﬁcantly worse outcome in temporal CRE
compared to extratemporal CRE. In the present study, two out of
8 patients (25%) with failure of the ﬁrst AED in patients with
temporal CRE and two out of 5 patients (40%) in patients withextratemporal CRE showed the good response to the second drug
regimen, although the difference was not statistically signiﬁcant
due to a small number of patients.
Epilepsy surgery is the most effective but often underutilized
therapeutic modality for patients suffering from DREs. Random-
ized controlled trials (RCTs) clearly demonstrated the superior
outcome of epilepsy surgery compared to that of continuing AEDs
therapy in patients with refractory TLE [20,21]. No RCTs for the
outcome of epilepsy surgery in patients with extra-TLE have been
conducted yet, however, a meta-analysis have shown that the
postsurgical outcome of extra-TLE was signiﬁcantly worse than
that of TLE with the presence of focal, resectable lesions in MRI
being the most important factor affecting the postsurgical
outcome in patients with DREs [22,23]. In the meta-analysis,
SFR after surgery in patients with epilepsy related to focal MRI-
lesions (lesional epilepsies) was 70% compared to 46% of non-
lesional epilepsies, which was a highly signiﬁcant difference [23].
These outcome studies made a basis for the recommendation of
earlier referral of patients to presurgical evaluation if they failed to
adequate therapeutic trials of two AEDs and their epilepsy
syndromes are considered surgically remediable.
Referral of patients with DRE to surgery is based on careful risk-
beneﬁt assessments in individual patients, which requires reliable
data on the postsurgical outcome. A review of previous surgical
series in patients with CRE showed Engel class-1 outcome in 70–
85% of patients, which seemed better or at least not worse than
that of surgery of TLE [2]. In a direct comparison of epilepsy surgery
of mesial TLE (MTLE) due to hippocampal sclerosis (HS) with MTLE
due to CM, the latter was associated with a signiﬁcantly better
postoperative outcome, however, DREs were more common in
patients with MTLE due to HS (88%) than MTLE due to CM (36%),
which made it as an unfair comparison [24]. In our study, the
outcome of lesionectomies in 5 patients who were conﬁrmed to
have refractory temporal CRE was excellent to achieve Engel class-
1 outcome in all patients without any permanent new neurological
deﬁcits, which was strongly in favor of surgery. However, a
comparative study of the early surgery and the conservative
management in newly diagnosed patients with CM showed
signiﬁcantly worse outcome in patients who underwent early
surgical excision [25]. In addition, another comparative study of
early surgery and medical treatment in patients with CRE did not
show any signiﬁcant differences in seizure outcomes between the
two groups [26]. Therefore, any recommendations proposing a
surgical excision of CM shortly after its diagnosis cannot be
justiﬁed by currently available evidence.
Considering the result of AEDs therapy and surgical outcomes of
refractory TLE in our patients and outcome data from previous
studies, different management strategies based on the location of
CM seems appropriate; failure to control seizures by adequate trial
of ﬁrst AED in patients with temporal CRE may be considered
justiﬁable for their referral to earlier surgery, while the second
drug trial is preferred in patients with extratemproal CRE due to a
reasonable chance of seizure remission and possibly higher risks
associated with extratemporal lobe surgery. However, future
controlled trials are in urgent need to provide evidence-based
guidelines.
Routine follow-up MRI in patients with CRE has been
recommended because CM is considered a dynamic vascular
abnormality [2]. Dynamic changes of CM may be related to
recurrent micro- or macro-hemorrhages followed by organization,
ﬁbrosis, and calciﬁcation. We obtained repeat MRIs in 20 patients
and found enlargement of CMs in two patients who were harboring
multiple CMs. This was in a strong contrast to the result of follow-
up MRIs in 16 patients with a single lesion, who did not show any
appreciable changes in the size of CM. The behavior of CM in
patients with a single CRE may be different from patients carrying
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focal neurological symptoms. The future guidelines of repeating
MRI in patients presenting with CRE may require further systemic
investigations.
The limitation of current study includes that the number of
enrolled patient was small and the study was a retrospective
hospital-based observational study, which may be associated with
signiﬁcant bias. However, all patients satisﬁed the strict inclusion
criteria, serial AEDs therapy was performed according to the
current practice guidelines, and seizure outcomes were assessed
appropriately during prolonged period of follow-up. It is surprising
to ﬁnd that, despite extensive clinical studies published in the
literature, there have been severe shortages of reliable information
related to the long-term outcome of AEDs therapy in patients with
newly diagnosed CRE. There is urgent need of controlled trials for
both medical and surgical treatments in patients with newly
diagnosed CRE.
In conclusion, the outcome of AEDs therapy in patients
presented with newly diagnosed CRE was quite comparable with
that of a hospital-based cohort of newly diagnosed epilepsy.
Location of CM in the temporal lobe was a single important factor
predicting poor outcome of AEDs therapy, which should be
addressed in a discussion with patient about the probabilities of
refractoriness and its consequences and the possibility of surgery
in short term. The probability of ﬁnding clinically meaningful
dynamic changes of CMs in patients with CRE was high in patients
with multiple CMs but quite low in cases with a single lesion.
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